Share on StockTwits

Tetraphase Pharmaceuticals (NASDAQ:TTPH) issued its quarterly earnings data on Tuesday. The company reported ($0.71) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.54) by $0.17, AmericanBankingNews.com reports. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.79 million.

A number of research firms have recently commented on TTPH. Analysts at Brean Capital initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, July 8th. They set a “buy” rating and a $23.00 price target on the stock. On a related note, analysts at TheStreet upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 20th. Finally, analysts at Gabelli initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Friday, June 20th. They set a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $18.75.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down 1.58% on Tuesday, hitting $11.83. The stock had a trading volume of 144,566 shares. Tetraphase Pharmaceuticals has a one year low of $8.00 and a one year high of $17.74. The stock has a 50-day moving average of $11.69 and a 200-day moving average of $11.75. The company’s market cap is $305.6 million.

Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.

Receive News & Ratings for Tetraphase Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.